ABSTRACT
Background Esophageal cancer (EC) is one of the most common cancer in the world and is the sixth leading cause of cancer-related mortality, where nearly half of the new EC cases are found in China, and esophageal squamous cell carcinoma (ESCC) is the preponderant type. Detection of early EC is essential to improving a patient’s survival. However, EC is a highly aggressive cancer with a poor prognosis, even for experienced endoscopists. Therefore, Computer-aided diagnosis (CAD) has become an important method to help endoscopists accurately and rapidly detect early detection.
Methods We proposed and developed a computer-assisted diagnosis AI system for early ESCC detection using advanced deep learning algorithms on the accurate endoscope magnified narrow-band imaging (ME-NBI) and the most referenced endoscope Lugol’s chromoendoscopy (LCE), which aimed to improve the detection on early ESCC.
Results All 3,500 images were collected from 800 enrolled patients. The CAD AI system contains 24 experiments and is able to detect the tumor region on both ME-NBI and LCE. Our proposed approach outperforms the current state-of-the-art and achieves 0.9236 mAP(mean average precision) on ME-NBI and 0.8620 mAP on LCE.
Conclusions The good diagnostic performance of our ESCC AI system has proven the feasibility of deep learning for detecting ESCC in both ME-NBI and LCE and shows great potential in applying the AI system in diagnosing the early stages of EC. Furthermore, collecting and analyzing the data of the patients from wider areas to achieve real-time performance for clinical applications have been added in our future plan.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Jinan healthcare science and technology plan(201907046), Shandong Province key research and development program (2019GSF108028) and Youth Natural Science Foundation of Shandong Province (ZR2020QH040).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of The first affiliated hospital of Shandong first Medical University (Shandong Provincial Qianfoshan hospital) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos